HomeENGLISH MAGAZINEPneumonia: discovered how it grows back from residual flu

Pneumonia: discovered how it grows back from residual flu

The situation is relatively common, especially in winter. You come down with the flu, which lasts longer than usual. A few days later, you discover you have pneumonia. The relationship between influenza and pneumonia has long been observed by health workers. Its genetic and cellular mechanisms have now been investigated in depth by scientists in a study involving volunteers and conducted in the United Kingdom. Published in the journal Nature Immunology, the paper describes for the first time a cellular mechanism that controls the proliferation of pneumococci – the Streptococcus pneumoniae bacteria that cause pneumonia – and their movement from the nose to the lungs. The study was performed by scientists at the Center for Research on Inflammatory Diseases – CRID, funded by São Paulo Research (FAPESP), and the Liverpool School of Tropical Medicine (LSTM) in the UK. Based on analysis of the cellular, genetic and immune response mechanisms, the team was able to prove that most flu-related deaths are due to post-flu pneumonia rather than to influenza virus itself. They also reports that in humans, the inflammation caused by the influenza virus impairs the innate immune control of this bacterium.

The main reason, according to the results of the study, is that influenza virus silences the organism’s innate immune response, in particular inhibiting the action of macrophages – the main type of leukocyte or white blood cell responsible for expelling foreign bodies such as viruses and bacteria. To conduct the study, the researchers recruited volunteers to be inoculated with attenuated influenza virus and pneumococcus. This procedure is permitted in the UK. No volunteers suffered from pneumonia during the study. Researchers on the Brazilian side analyzed and interpreted genetic and cellular data using CEMiTool bioinformatics software developed at the University of São Paulo’s Pharmaceutical Science School (FCF-USP) with FAPESP’s support under the aegis of its Young Investigators grant program. Live attenuated influenza viruses were obtained from the flu vaccines (Fluenz/Flumist) administered every winter in the UK. Three days after receiving the flu virus, the volunteers received pneumococcus via nasal spray. Blood samples, nasal swabs and nasal cells from the volunteers were analyzed throughout the study, which lasted an entire winter.

The findings showed that the number of bacteria in the nose increased significantly because of the influenza virus. The bacteria multiply in the nose when the influenza virus impairs the immune response by inhibiting monocyte antibacterial activity. Daniela Ferreira, a professor at LSTM and main investigator, explained thoroughly: “In order for pneumonia to develop, the bacterium must be in the lungs. This same bacterium can live in the nose for a long time without causing symptoms, especially in healthy adults. For some reason, however, especially in more vulnerable patients, the bacterium travels from the nose to the lungs. Our study focused precisely on the mechanisms that clear the bacteria from the nose and prevent it from traveling to the lungs, and on how influenza virus alters this process. Another important point is that excessive multiplication of pneumococcus heightens the patient’s predisposition to transmit it to other people. There are two problems: an increase in individual susceptibility to pneumonia, and an increase in transmission of pneumococcus in the general population. Therefore, we analyzed the genes and mechanisms involved in the bacterium’s journey to the lungs. We also identified biological markers that are more expressed in an individual with the virus and uncontrolled bacterial infection.

The mechanisms of the immune response to colonization by pneumococcus have been thoroughly studied in mice but remain poorly understood in humans. Using for the first time a human experimental challenge model with the attenuated flu virus and pneumococcus, the researchers discovered that in humans, unlike mice, nasal bacterial infection leads quickly to the activation of neutrophils, another type of lymphocyte always present in the human nose, and to the recruitment of monocytes, which clear the nostrils of bacteria by rupturing their vesicles (lysis). Neutrophil recruitment results in control of the bacteria in mice, instead of monocyte recruitment. Another finding was that the live attenuated influenza vaccine can be used to control pneumonia, which is a major global health problem and kills more children under five than any other disease. It is also particularly dangerous to the elderly and people with chronic lung disease, immunosuppression and viral coinfection. “The most important point about this entire process is that people need to be immune to flu. The flu vaccine also proved beneficial to avoiding pneumonia,” Ferreira said.

The researchers are now analyzing the converse situation when infection by the bacteria occurs first and is followed by influenza virus infection.

  • Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.

Scientific references

Jochems SP et al., Ferreira DM. Nat Immunol. 2018 Dec; 19:1299-1308. 

Russo PS et al., Nakaya HI. BMC Bioinformatics 2018 Feb; 19(1):56. 

Ishiguro T, Kagiyama et al. Yale J Biol Med. 2017 Jun; 90(2):165-181. 

Asai N et al.,  Yamagishi Y. BMC Infect Dis. 2017 Aug 15; 17(1):572.

The following two tabs change content below.

Dott. Gianfrancesco Cormaci

Medico Chirurgo, Specialista; PhD. a CoFood s.r.l.
- Laurea in Medicina e Chirurgia nel 1998 (MD Degree in 1998) - Specialista in Biochimica Clinica nel 2002 (Clinical Biochemistry residency in 2002) - Dottorato in Neurobiologia nel 2006 (Neurobiology PhD in 2006) - Ha soggiornato negli Stati Uniti, Baltimora (MD) come ricercatore alle dipendenze del National Institute on Drug Abuse (NIDA/NIH) e poi alla Johns Hopkins University, dal 2004 al 2008. - Dal 2009 si occupa di Medicina personalizzata. - Guardia medica presso strutture private dal 2010 - Detentore di due brevetti sulla preparazione di prodotti gluten-free a partire da regolare farina di frumento enzimaticamente neutralizzata (owner of patents concerning the production of bakery gluten-free products, starting from regular wheat flour). - Responsabile del reparto Ricerca e Sviluppo per la società CoFood s.r.l. (Leader of the R&D for the partnership CoFood s.r.l.) - Autore di articoli su informazione medica e salute sul sito www.medicomunicare.it (Medical/health information on website) - Autore di corsi ECM FAD pubblicizzati sul sito www.salutesicilia.it
- Advertisment -